Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.19873 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Registries in allergy: Structure, target groups, and key findings of allergy-focused registries in Germany.
Allergol Select
December 2024
Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
In allergology, clinical registries fill knowledge gaps of epidemiology, mechanisms of allergic diseases, and real-world treatment outcomes. Considering the continuous rise of allergic diseases worldwide, registries become increasingly important for the optimization and harmonization of patient care. In the current review, we present four ongoing allergy-focused registries initiated in Germany.
View Article and Find Full Text PDFA real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries.
J Dermatolog Treat
December 2025
Sanofi-Evidence Generation and Dissemination Manager Greater Gulf, UAE.
Purpose/aim Of The Study: There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.
Materials And Methods: This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days.
Tumors in the setting of dupilumab use: A review of the literature.
World Allergy Organ J
January 2025
Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China.
Dupilumab is the first monoclonal antibody approved for treating moderate-to-severe atopic dermatitis (AD) and has significantly improved the quality of life of AD patients. However, the safety of dupilumab is yet unclear in the context of cancer. Therefore, we aimed to investigate the safety of dupilumab and its relationship with the progression and occurrence of tumors.
View Article and Find Full Text PDFEfficacy of dupilumab with concomitant topical calcineurin inhibitors treatment for preschool children with atopic dermatitis: a retrospective cohort study.
Ann Med
December 2025
Department of Dermatology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Background/objective: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that typically occurs in childhood/infancy and is associated with complications like extracutaneous atopic morbidity. Providing systemic treatment for pediatric AD patients with unmet comprehensive medical needs remains challenging. We present a cohort study describing the efficacy and safety of dupilumab combined with topical calcineurin inhibitors (TCI) in children with moderate-to-severe atopic dermatitis under the age of 6 years.
View Article and Find Full Text PDF[Annual research progress in chronic obstructive pulmonary disease 2024].
Zhonghua Jie He He Hu Xi Za Zhi
January 2025
National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Hetao Institute of Guangzhou National Laboratory, Shenzhen518000, China.
Article Synopsis
- COPD is a growing global health issue, with recent advancements in early detection and personalized treatment, highlighting the importance of monitoring early-stage disease for better prognosis.
- Research has identified critical areas in the lungs as initial sites of damage, and specific biomarkers may help track different disease progression patterns.
- New treatment strategies, including triple inhalation therapy and innovative medications, show promise in managing symptoms and improving patient outcomes in COPD, with ongoing research aimed at understanding disease variability.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!